PDT Partners LLC Cuts Stock Holdings in DaVita Inc. (NYSE:DVA)

PDT Partners LLC lowered its stake in DaVita Inc. (NYSE:DVA - Free Report) by 14.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,080 shares of the company's stock after selling 3,807 shares during the quarter. PDT Partners LLC's holdings in DaVita were worth $3,452,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DVA. Invesco Ltd. increased its position in DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after buying an additional 275,284 shares in the last quarter. Northern Trust Corp grew its position in shares of DaVita by 12.5% during the fourth quarter. Northern Trust Corp now owns 740,774 shares of the company's stock valued at $110,783,000 after purchasing an additional 82,326 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Amundi lifted its holdings in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after acquiring an additional 240,126 shares during the last quarter. Finally, Epoch Investment Partners Inc. purchased a new position in shares of DaVita in the 4th quarter worth approximately $55,100,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA traded up $0.47 during trading on Friday, reaching $140.91. 574,972 shares of the company's stock were exchanged, compared to its average volume of 831,164. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company's fifty day simple moving average is $146.09 and its 200-day simple moving average is $154.77. DaVita Inc. has a 1 year low of $131.27 and a 1 year high of $179.60. The stock has a market capitalization of $11.27 billion, a P/E ratio of 13.12, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on DVA shares. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.